Literature DB >> 1081857

The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.

B L Gordon, J P Keenan.   

Abstract

A 23-year-old woman with a nine-month history of SLE, uncontrolled with high daily doses of steroids, was treated with the T-cell immunostimulant drug, levamisole. Following a single oral three-day course of therapy with this agent her immunologic parameters and clinical manifestations underwent marked regression. Continuous two-weekly course of this drug at three days per course have allowed rapid reduction of her steroid and resulted in complete remission of her symptoms. The theoretical considerations for the use of levamisole dovetailed perfectly with the observed response to this agent.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1081857

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  4 in total

1.  The effect of Levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  M Rosenthal; U Trabert; W Müller
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

2.  Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole.

Authors:  W De Cock; J De Cree; H Verhaegen
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

3.  Lysosomal enzymes and metabolic activity of polymorphonuclear leukocytes from patients with systemic lupus erythematosus and from experimental animals after levamisole treatment.

Authors:  M Ferencík; J Rovenský; J Stefanovic
Journal:  Agents Actions       Date:  1982-10

4.  The in vitro effect of thymic humoral factor and levamisole on peripheral blood lymphocytes in systemic lupus erythematosus patients.

Authors:  R Michalevicz; A Many; B Ramot; N Trainin
Journal:  Clin Exp Immunol       Date:  1978-01       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.